US2007207964A1PendingUtilityA1

Combined use of a GLP-1 compound and another drug for treating dyslipidemia

54
Individually held — no corporate assignee on recordPriority: Dec 29, 2001Filed: May 3, 2007Published: Sep 6, 2007
Est. expiryDec 29, 2021(expired)· nominal 20-yr term from priority
Inventors:Lotte Bjerre KnudsenJohan Selmer
A61P 43/00A61P 3/06A61K 31/225A61K 38/26A61K 31/785A61K 31/401A61P 3/00A61K 31/366A61K 45/06
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Claims

exact text as granted — not AI-modified
1 .- 22 . (canceled)  
   
   
       23 . A method for treating dyslipidemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of a squalene synthase inhibitor.  
   
   
       24 . The method according to  claim 23 , wherein the GLP-1 compound is GLP-1 (7-37) or an analog or derivative thereof.  
   
   
       25 . The method according to  claim 24 , wherein the GLP-1 compound is an analog of GLP-1 (7-37).  
   
   
       26 . The method according to  claim 25 , wherein the analog of GLP-1 (7-37) has less than five amino acid residues different from those of GLP-1 (7-37).  
   
   
       27 . The method according to  claim 26 , wherein the analog of GLP-1 (7-37) has less than three amino acid residues different from those of GLP-1 (7-37).  
   
   
       28 . The method according to  claim 24 , wherein the GLP-1 compound is a derivative of GLP-1 (7-37).  
   
   
       29 . The method according to  claim 28 , wherein said derivative is acylated at at least one of the amino acids of GLP-1 (7-37).  
   
   
       30 . The method according to  claim 24 , wherein said GLP-1 compound is a derivative of an analog of GLP-1 (7-37).  
   
   
       31 . The method according to  claim 30 , wherein said derivative is acylated at at least one of the amino acids of said analog of GLP-1 (7-37).  
   
   
       32 . The method according to  claim 31 , wherein the analog of GLP-1 (7-37) has less than five amino acid residues different from those of GLP-1 (7-37).  
   
   
       33 . The method according to  claim 32 , wherein the analog of GLP-1 (7-37) has less than three amino acid residues different from those of GLP-1 (7-37).  
   
   
       34 . The method according to  claim 33 , wherein the derivative is Arg 34 , Lys 26 (N ε -(γ-Glu(N α -hexadecanoyl)))-GLP-1 (7-37).  
   
   
       35 . The method according to  claim 33 , wherein the GLP-1 compound is exendin-4 or an analog or derivative thereof.  
   
   
       36 . The method according to  claim 35 , wherein the GLP-1 compound is exendin 4.  
   
   
       37 . The method according to  claim 35 , wherein the GLP-1 compound is an analog of exendin-4.  
   
   
       38 . The method according to  claim 33 , wherein the GLP-1 compound and the squalene synthase inhibitor are administered separately.  
   
   
       39 . The method according to  claim 39 , wherein the GLP-1 compound is administered parenterally.  
   
   
       40 . The method according to  claim 39 , wherein the squalene synthase inhibitor is administered orally.  
   
   
       41 . The method according to  claim 33 , wherein the GLP-1 compound and the squalene synthase inhibitor are administered simultaneously.  
   
   
       42 . The method according to claim  21 , wherein the GLP-1 compound and the squalene synthase inhibitor are administered as a single formulation.  
   
   
       43 . The method according to  claim 42 , wherein the single formulation is administered parenterally.  
   
   
       44 . The method according to  claim 33 , wherein said squalene synthase inhibitor is YM-53601.  
   
   
       45 . The method according to  claim 33 , wherein said squalene synthase inhibitor is ER-27856.  
   
   
       46 . A method for treating dyslipidemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of an ileal bile acid co-transporter (IBAT) inhibitor.  
   
   
       47 . The method according to  claim 46 , wherein said IBAT inhibitor is S-8921.  
   
   
       48 . The method according to  claim 46 , wherein the GLP-1 compound is GLP-1 (7-37) or an analog or derivative thereof.  
   
   
       49 . The method according to  claim 48 , wherein the GLP-1 compound is an analog of GLP-1 (7-37).  
   
   
       50 . The method according to  claim 49 , wherein the analog of GLP-1 (7-37) has less than five amino acid residues different from those of GLP-1 (7-37).  
   
   
       51 . The method according to  claim 50 , wherein the analog of GLP-1 (7-37) has less than three amino acid residues different from those of GLP-1 (7-37).  
   
   
       52 . The method according to  claim 48 , wherein the GLP-1 compound is a derivative of GLP-1 (7-37).  
   
   
       53 . The method according to  claim 52 , wherein said derivative is acylated at at least one of the amino acids of GLP-1 (7-37).  
   
   
       54 . The method according to  claim 48 , wherein said GLP-1 compound is a derivative of an analog of GLP-1 (7-37).  
   
   
       55 . The method according to  claim 54 , wherein said derivative is acylated at at least one of the amino acids of said analog of GLP-1 (7-37).  
   
   
       56 . The method according to  claim 55 , wherein the analog of GLP-1 (7-37) has less than five amino acid residues different from those of GLP-1 (7-37).  
   
   
       57 . The method according to  claim 56 , wherein the analog of GLP-1 (7-37) has less than three amino acid residues different from those of GLP-1 (7-37).  
   
   
       58 . The method according to  claim 57 , wherein the derivative is Arg 34 , Lys 26 (N ε -(γ-Glu(N α -hexadecanoyl)))-GLP-1 (7-37).  
   
   
       59 . The method according to  claim 46 , wherein the GLP-1 compound is exendin-4 or an analog or derivative thereof.  
   
   
       60 . The method according to  claim 59 , wherein the GLP-1 compound is exendin 4.  
   
   
       61 . The method according to  claim 59 , wherein the GLP-1 compound is an analog of exendin-4.  
   
   
       62 . The method according to  claim 46 , wherein the GLP-1 compound and the IBAT inhibitor are administered separately.  
   
   
       63 . The method according to  claim 62 , wherein the GLP-1 compound is administered parenterally.  
   
   
       64 . The method according to  claim 62 , wherein the IBAT inhibitor is administered orally.  
   
   
       65 . The method according to  claim 46 , wherein the GLP-1 compound and the IBAT inhibitor are administered simultaneously.  
   
   
       66 . The method according to  claim 65 , wherein the GLP-1 compound and the IBAT inhibitor are administered as a single formulation.  
   
   
       67 . The method according to  claim 66 , wherein the single formulation is administered parenterally.  
   
   
       68 . A method for treating hyperlipidemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of a squalene synthase inhibitor.  
   
   
       69 . A method for treating hypertriglyceridemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of a squalene synthase inhibitor.  
   
   
       70 . A method for treating hyperlipidemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of an ileal bile acid co-transporter (IBAT) inhibitor.  
   
   
       71 . A method for treating hypertriglyceridemia in a patient, said method comprising administering to a patient in need of such treatment an effective amount of a glucagon-like peptide 1 (GLP-1) compound and an effective amount of an ileal bile acid co-transporter (IBAT) inhibitor.

Join the waitlist — get patent alerts

Track US2007207964A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.